New treatment option for older patients with blood cancer
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
Visitor information – Everything you need to know about visiting our sites.
Our group uses transgenic mouse models and ES / iPS (embryonic stem / induced pluripotent stem) cell-based technologies to study cell fate and cellular transformation at the molecular level.
We are elucidating the role of the ZEB and SNAI family of transcription factors in normal haematopoietic stem cell differentiation and lineage commitment, as well as their roles in the development of leukaemic cancer stem cells with a focus on T-cell ALL (Goossens S et al., Nat Commun 2015).
Find out more about the Mammalian Functional Genetics Unit
Researchers are a step closer to offering older patients with an aggressive blood cancer, acute myeloid leukaemia (AML), a new less-toxic treatment option.
The Alfred and Monash University are set to establish Australia’s first dedicated blood cancer research centre, thanks to a $1.2 million grant from the Australian Cancer Research Foundation (ACRF).